Results from a clinical validation study show that Diadem’s AlzoSure, a blood-based biomarker test, accurately predicts progression to Alzheimer’s disease (AD) up to six years prior to diagnosis. The data from the retrospective longitudinal study has been made available in a medRxiv preprint before its submission to the Journal of Neuroscience.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,